- Page 1 and 2:
After Heparin: Protecting Consumers
- Page 3 and 4:
TABLE OF CONTENTS 1.4 Problems with
- Page 5 and 6:
Executive Summary In late 2007, U.S
- Page 7 and 8:
Executive Summary eventually being
- Page 9 and 10:
Introduction and Background U.S. ph
- Page 11 and 12:
INTRODUCTION AND BACKGROUND less ri
- Page 13 and 14:
50 0 INTRODUCTION AND BACKGROUND un
- Page 15 and 16:
INTRODUCTION AND BACKGROUND in Chin
- Page 17 and 18:
CHAPTER1 PHARMACEUTICAL MANUFACTURI
- Page 19 and 20:
PHARMACEUTICAL MANUFACTURING: GLOBA
- Page 21 and 22:
PHARMACEUTICAL MANUFACTURING: GLOBA
- Page 23 and 24:
PHARMACEUTICAL MANUFACTURING: GLOBA
- Page 25 and 26:
PHARMACEUTICAL MANUFACTURING: GLOBA
- Page 27 and 28:
PHARMACEUTICAL MANUFACTURING: GLOBA
- Page 29 and 30:
PHARMACEUTICAL MANUFACTURING: GLOBA
- Page 31 and 32:
PHARMACEUTICAL MANUFACTURING: GLOBA
- Page 33 and 34:
PHARMACEUTICAL MANUFACTURING: GLOBA
- Page 35 and 36:
PHARMACEUTICAL MANUFACTURING: GLOBA
- Page 37 and 38:
PHARMACEUTICAL MANUFACTURING: GLOBA
- Page 39 and 40:
PHARMACEUTICAL MANUFACTURING: GLOBA
- Page 41 and 42:
500000000 0 —Chapter 2— Figure
- Page 43 and 44:
—Chapter 2— FDA inspected only
- Page 45 and 46:
—Chapter 2— foreign offices hav
- Page 47 and 48:
—Chapter 2— plants. However, th
- Page 49 and 50:
—Chapter 2— Revived use of the
- Page 51 and 52:
—Chapter 2— 2.5 Pew conference
- Page 53 and 54:
—Chapter 2— 2. Use comprehensiv
- Page 55 and 56: —Chapter 2— 3. Allow the FDA to
- Page 57 and 58: CHAPTER3 PHARMACEUTICAL DISTRIBUTIO
- Page 59 and 60: PHARMACEUTICAL DISTRIBUTION As dist
- Page 61 and 62: PHARMACEUTICAL DISTRIBUTION Case st
- Page 63 and 64: PHARMACEUTICAL DISTRIBUTION Sidebar
- Page 65 and 66: PHARMACEUTICAL DISTRIBUTION which i
- Page 67 and 68: PHARMACEUTICAL DISTRIBUTION the age
- Page 69 and 70: PHARMACEUTICAL DISTRIBUTION 3.4 Pew
- Page 71 and 72: PHARMACEUTICAL DISTRIBUTION d. If t
- Page 73 and 74: REFERENCES 16 Fagan, Kevin. Testimo
- Page 75 and 76: REFERENCES 58 Schwartzkopff, France
- Page 77 and 78: REFERENCES 111 NSD Bio Group. “Po
- Page 79 and 80: REFERENCES 155 State Food and Drug
- Page 81 and 82: REFERENCES 195 U.S. Food and Drug A
- Page 83 and 84: REFERENCES 244 U.S. Food and Drug A
- Page 85 and 86: REFERENCES 289 U.S. Food and Drug A
- Page 87 and 88: REFERENCES 332 Public Law 111-8—M
- Page 89 and 90: REFERENCES 378 Villax, Guy. Board M
- Page 91 and 92: REFERENCES 429 U.S. Supreme Court,
- Page 93 and 94: REFERENCES 479 Michelle M. Ciolek,
- Page 95 and 96: REFERENCES 521 21 USC §828 (a). 52
- Page 97 and 98: APPENDIX A Expert Interviews Bill A
- Page 99 and 100: APPENDIX B Pew Stakeholder Conferen
- Page 101 and 102: APPENDIX C Pew Stakeholder Conferen
- Page 103 and 104: Pew Stakeholder Conference Agenda T
- Page 105: acknowledgments We gratefully ackno